BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 35581611)

  • 21. Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis.
    Shaw LK; Wiele AJ; Sircar K; Wood CG; Msaouel P
    Cancer Treat Res Commun; 2021; 27():100349. PubMed ID: 33725559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
    Kim S; Wuthrick E; Blakaj D; Eroglu Z; Verschraegen C; Thapa R; Mills M; Dibs K; Liveringhouse C; Russell J; Caudell JJ; Tarhini A; Markowitz J; Kendra K; Wu R; Chen DT; Berglund A; Michael L; Aoki M; Wang MH; Hamaidi I; Cheng P; de la Iglesia J; Slebos RJ; Chung CH; Knepper TC; Moran-Segura CM; Nguyen JV; Perez BA; Rose T; Harrison L; Messina JL; Sondak VK; Tsai KY; Khushalani NI; Brohl AS
    Lancet; 2022 Sep; 400(10357):1008-1019. PubMed ID: 36108657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors.
    Nemoto Y; Ishihara H; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Kondo T; Takagi T
    Jpn J Clin Oncol; 2023 Jun; 53(7):611-618. PubMed ID: 37002188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma.
    Singla N; Elias R; Ghandour RA; Freifeld Y; Bowman IA; Rapoport L; Enikeev M; Lohrey J; Woldu SL; Gahan JC; Bagrodia A; Brugarolas J; Hammers HJ; Margulis V
    Urol Oncol; 2019 Dec; 37(12):924-931. PubMed ID: 31522865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
    Atkins MB; Jegede OA; Haas NB; McDermott DF; Bilen MA; Stein M; Sosman JA; Alter R; Plimack ER; Ornstein MC; Hurwitz M; Peace DJ; Signoretti S; Denize T; Cimadamore A; Wu CJ; Braun D; Einstein D; Catalano PJ; Hammers H
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36948504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report.
    Iribe Y; Furuya M; Shibata Y; Yasui M; Funahashi M; Ota J; Iwashita H; Nagashima Y; Hasumi H; Hayashi N; Makiyama K; Kondo K; Tanaka R; Yao M; Nakaigawa N
    Fam Cancer; 2021 Jan; 20(1):75-80. PubMed ID: 32666341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [DEFERRED NEPHRECTOMY IN A PATIENT WITH METASTATIC RENAL CELL CARCINOMA AFTER A NEAR-COMPLETE RESPONSE TO IMMUNOTHERAPY].
    Purim O; Raz O; Eisner A; Baram N; Leonov Polak M; Rybo L
    Harefuah; 2022 Dec; 161(12):763-768. PubMed ID: 36916116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nivolumab and ipilimumab immunotherapy for hemodialysis patients with advanced renal cell carcinoma.
    Kobayashi Y; Arai H; Honda M
    Curr Oncol; 2020 Aug; 27(4):225-228. PubMed ID: 32905370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
    Grimm MO; Grün CB; Niegisch G; Pichler M; Roghmann F; Schmitz-Dräger B; Baretton G; Schmitz M; Bolenz C; Foller S; Leucht K; Schumacher U; Schostak M; Meran J; Loidl W; Zengerling F
    Lancet Oncol; 2023 Apr; 24(4):347-359. PubMed ID: 36868252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 detection using
    Vento J; Mulgaonkar A; Woolford L; Nham K; Christie A; Bagrodia A; de Leon AD; Hannan R; Bowman I; McKay RM; Kapur P; Hao G; Sun X; Brugarolas J
    J Immunother Cancer; 2019 Jun; 7(1):144. PubMed ID: 31155004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma.
    Danno T; Iwata S; Niimi F; Honda S; Okada H; Azuma T
    Case Rep Urol; 2021; 2021():9936330. PubMed ID: 34306793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice.
    Massari F; Nunno VD; Mollica V; Montironi R; Cheng L; Cimadamore A; Blanca A; Lopez-Beltran A
    Immunotherapy; 2019 Dec; 11(17):1507-1521. PubMed ID: 31663411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperprogressive Disease In a Metastatic Renal Cell Carcinoma Patient After Receiving Immune Checkpoint Inhibitors: A Case Report.
    Alkader M; Altaha R; Alkhatib L; Jabali EH; Alsoreeky MS
    Cureus; 2022 Oct; 14(10):e30194. PubMed ID: 36381823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 Therapy.
    Carril-Ajuria L; Lora D; Carretero-González A; Martín-Soberón M; Rioja-Viera P; Castellano D; de Velasco G
    Clin Genitourin Cancer; 2021 Apr; 19(2):95-102. PubMed ID: 33189597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
    Tykodi SS; Gordan LN; Alter RS; Arrowsmith E; Harrison MR; Percent I; Singal R; Van Veldhuizen P; George DJ; Hutson T; Zhang J; Zoco J; Johansen JL; Rezazadeh Kalebasty A
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases.
    de Peralta-Venturina M; Moch H; Amin M; Tamboli P; Hailemariam S; Mihatsch M; Javidan J; Stricker H; Ro JY; Amin MB
    Am J Surg Pathol; 2001 Mar; 25(3):275-84. PubMed ID: 11224597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
    Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis.
    Quhal F; Mori K; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Curr Opin Urol; 2022 Jan; 32(1):61-68. PubMed ID: 34720102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.